Showing results (121-130 of 232) with videos related to

Sort By:
Pageof 24
Tumori|January 5, 2002
Nuclear medicine advances in breast cancer imagingE Bombardieri, F Crippa, S M Baio, et al.
Journal of Biological Regulators and Homeostatic Agents|October 1, 1994
Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patientsA Bogni, A Cortinois, G Grasselli, et al.
Anticancer Research|January 1, 1997
Cancer of the uterine cervix: clinical value of squamous cell carcinoma antigen (SCC) measurementsL Lozza, M Merola, R Fontanelli, et al.
International Journal of Oncology|April 14, 1999
Current applications and perspectives of diagnostic nuclear medicine in oncology. Task Group of OncologyE Bombardieri, I Carrio, P Gonzalez, et al.
Nuclear Medicine Communications|March 16, 2000
Toxicity of high-activity 111In-Octreotide therapy in patients with disseminated neuroendocrine tumoursM E Caplin, W Mielcarek, J R Buscombe, et al.
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies|March 1, 1994
Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre studyW Ebert, H Dienemann, A Fateh-Moghadam, et al.
The International Journal of Biological Markers|April 1, 1993
Mucin-like carcinoma-associated antigen (MCA) in breast cancer: clinical experience at the National Cancer Institute of MilanE Seregni, F Crippa, C Botti, et al.
Lung Cancer (Amsterdam, Netherlands)|July 1, 1997
Intensification of 111In-DTPA-octreotide scintigraphy by means of pretreatment with cold octreotide in small cell lung cancerE Soresi, G Invernizzi, R Boffi, et al.
Nuclear Medicine Communications|December 16, 1998
Use of 99Tcm-MIBI in the assessment of patients with suspected recurrent breast cancerJ B Cwikla, J R Buscombe, S P Parbhoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2009
Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II studyJ B Cwikla, A Sankowski, N Seklecka, et al.
Pageof 24